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Although there is no standardised definition of an ultra-rare disease, pulmonary 
veno-occlusive disease (PVOD) would certainly qualify. The condition has a 
prevalence of less than 1 per million of the population, and yet most physicians are 
familiar with the term. PVOD is classified as a rare form of pulmonary arterial 
hypertension (PAH) (1). The disease usually manifests in younger adults and is 
considered to carry a particularly poor prognosis compared with other forms of PAH. 
Amongst pulmonary hypertension specialists it is an unwelcome diagnosis since it 
has a reputation for responding poorly to available PAH therapies, and indeed these 
therapies may precipitate fatal pulmonary oedema (2, 3). Being an ultra-rare 
condition, PVOD has retained an aura of mystery, but now the paper by Montani et 
al. in this issue of the Lancet Respiratory Medicine provides new insights into the 
molecular and clinical characterisation of this disease in the largest published cohort 
to date.  
 
The paper by Montani et al. follows up on the recent discovery of biallelic mutations 
in the EIF2AK4 gene as the major genetic cause of PVOD. Recessive mutations in 
EIF2AK4 account for nearly 100% of families with PVOD, and approximately 25% of 
sporadic cases (4). The finding of biallelic EIF2AK4 mutations in cases of pulmonary 
capillary haemangiomatosis (PCH) also suggests that PVOD and PCH are 
essentially manifestations of the same disease (5). The present paper describes the 
clinical course of disease in PVOD/PCH patients with and without biallelic EIF2AK4 
mutations. Mutation carriers had a significantly younger age of diagnosis and 
subsequently were more likely to be transplanted.  However, no survival difference 
was demonstrated between the two groups. Additionally, lung function and 
haemodynamic parameters were similar to those with no EIF2AK4 mutations. As 
reported in a previous publication by the group, patients without EIF2AK4 mutations 
were far more likely to have been exposed to inorganic solvents as well as to have 
received chemotherapy prior to the development of disease (6).  
 
Thus the genetic and environmental factors involved in the aetiology of PVOD/PCH 
are becoming clearer. What remains unclear are the mechanisms by which these 
mutations and indeed the exposure to noxious agents, precipitates disease. It is 
remarkable that mutations in EIF2AK4, a ubiquitously expressed kinase of the cell 
integrated stress response, typically in response to amino acid deprivation, manifest 
as this rare lung disease. Pre-clinical models have shown that phenotypic expression 
of the EIF2AK4 knockout requires additional environmental stresses such as amino 
acid starvation (7). Whether such stresses influences disease manifestation in 
humans with biallelic EIF2AK4 mutations has not been explored. Much remains to be 
discovered regarding the mechanisms, and whether this might yield new approaches 
to treating this devastating disease. 
 
The present report confirms that the clinical response to therapies currently licensed 
for PAH is very modest in patients with PVOD/PCH. This observation, coupled with a 
risk of life-threatening pulmonary oedema precipitated by these drugs in over 20% of 
cases, should prompt the physician to refer for early assessment for lung 
transplantation. Although overall clinical improvement in response to drug therapy 
was modest, it might be possible in future studies to stratify PVOD/PCH patients 
based on risk of pulmonary oedema or genotype.  
 
Finally, the distinction between PVOD and PAH can be subtle. Up to 10% of patients 
with a clinical diagnosis of idiopathic PAH may have evidence for PVOD. Clinical 
characteristics such as a low transfer coefficient for carbon monoxide have also 
been described in a subset of patients with PAH, as have radiological features such 
centrilobular ground-glass opacification (8). The gold standard for diagnosis of 
PVOD/PCH is histological assessment. However, since lung biopsy is 
contraindicated in PAH such confirmation usually occurs only following death or 
transplantation. The finding of bilallelic mutations in EIF2AK4 might now be used to 
confirm a suspected diagnosis, but confounding this there have been reports of 
families with biallelic mutations in EIF2AK4 where the diagnosis was thought to be 
PAH (9, 10). We believe these reports are more likely to be examples of mis-
classification of PAH, although analysis of EIF2AK4 mutations in larger cohorts of 
PAH patients will be required to confirm this. The finding of an isolated markedly 
reduced diffusion capacity for carbon monoxide is a consistent feature of such 
patients, which strongly suggests underlying PVOD/PCH. 
 
The paper by Montani et al provides a definitive description of PVOD/PCH and the 
impact of EIF2AK4 mutations.  This series, all enrolled in the French Pulmonary 
Hypertension Registry, is the largest to date.  However, even larger international 
collaborations will be required to have sufficient power to identify and explain the 
heterogeneity in phenotypes observed and provide further clues to the mechanisms 
by which these arise.  
 
1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. 
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 
Suppl):D34-41. 
2. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive 
pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-
occlusive disease. Chest. 1998;113(1):237-40. 
3. Montani D, Achouh L, Dorfmuller P, Le Pavec J, Sztrymf B, Tcherakian C, et al. 
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic 
characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 
2008;87(4):220-33. 
4. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. EIF2AK4 mutations 
cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat 
Genet. 2014;46(1):65-9. 
5. Best DH, Sumner KL, Austin ED, Chung WK, Brown LM, Borczuk AC, et al. EIF2AK4 
mutations in pulmonary capillary hemangiomatosis. Chest. 2014;145(2):231-6. 
6. Montani D, Lau EM, Descatha A, Jais X, Savale L, Andujar P, et al. Occupational 
exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir 
J. 2015;46(6):1721-31. 
7. Zhang P, McGrath BC, Reinert J, Olsen DS, Lei L, Gill S, et al. The GCN2 eIF2alpha 
kinase is required for adaptation to amino acid deprivation in mice. Mol Cell Biol. 
2002;22(19):6681-8. 
8. Rajaram S, Swift AJ, Condliffe R, Johns C, Elliot CA, Hill C, et al. CT features of 
pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 
patients from the ASPIRE Registry. Thorax. 2015;70(4):382-7. 
9. Tenorio J, Navas P, Barrios E, Fernandez L, Nevado J, Quezada CA, et al. A founder 
EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian 
Gypsies. Clin Genet. 2014. 
10. Best DH, Sumner KL, Smith BP, Damjanovich-Colmenares K, Nakayama I, Brown LM, 
et al. EIF2AK4 Mutations in Patients Diagnosed with Pulmonary Arterial Hypertension. 
Chest. 2016. 
 
